

SUPPLEMENTAL AMENDMENT

Please amend the above referenced application as follows:

In the Claims

Please ~~cancel~~ claim 24 without prejudice, amend claims 20, 21, and 25, and add new independent claim 26 as set forth below:

AMENDED CLAIM 20

¹⁶
--~~20~~. (Amended) The antibody of Claim ~~19~~, wherein the antibody is [being] administered in association with an extracorporeal circulation procedure.--

AMENDED CLAIM 21

¹⁷
--21. (Amended) A sterile non-pyrogenic therapeutic agent [for use in association with extracorporeal circulation procedures, wherein the therapeutic agent is sterile and non-pyrogenic and comprises] comprising the antibody of Claim 1 and a pharmaceutically effective carrier.--

AMENDED CLAIM 25

¹⁷
--~~25~~. (Amended) The therapeutic agent of Claim [24] ¹⁷~~21~~ wherein the antibody is [a humanized antibody] made up of two or more heterodimeric subunits each containing one heavy and one light chain.--

NEW CLAIM 26

¹⁸
--~~26~~. Antibody 5G1.1 scFv CB (humanized) having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:8.

Remarks

This is supplemental to the supplemental amendments of January 11, 1999, November 4, 1998, and the response, mailed August 14, 1998, to the Office Action dated February 18, 1998 in the above referenced application. No extension of time is believed to be required for this paper, but should any such extension be required the Commissioner is requested to consider this a petition therefor. The Commissioner is